"An über 10 verschiedenen Standorten sind wir Ihr vertrauensvoller Ansprechpartner für Dialyse im Schwarzwald"

During the past decade, Nephrologisches Zentrum Villingen-Schwenningen conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nephrologisches Zentrum Villingen-Schwenningen" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "Amgen" with 1 trials sponsored, "Chinook Therapeutics U.S., Inc." with 1 trials sponsored, "Genzyme, a Sanofi Company" with 1 trials sponsored and "KBP Biosciences" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nephrologisches Zentrum Villingen-Schwenningen" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "Kaneka Pharma Europe N.V." with 1 trials as a collaborator and "Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Nephrologisches Zentrum Villingen-Schwenningen" are "Chronic Kidney Disease" (3 trials), "Chronic Kidney Diseases" (1 trials), "Coronary Heart Disease (CHD)" (1 trials), "End Stage Renal Disease" (1 trials) and "Focal Segmental Glomerulosclerosis (FSGS)" (1 trials). Many other conditions were trialed in "Nephrologisches Zentrum Villingen-Schwenningen" in a lesser frequency.

Most popular intervention types in "Nephrologisches Zentrum Villingen-Schwenningen" are "Drug" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Atrasentan" (1 trials), "BI 685509" (1 trials), "Empagliflozin" (1 trials) and "Evolocumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nephrologisches Zentrum Villingen-Schwenningen" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Nephrologisches Zentrum Villingen-Schwenningen". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Nephrologisches Zentrum Villingen-Schwenningen, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Nephrologisches Zentrum Villingen-Schwenningen, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".